Since its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.
- Strategic alliance with Gilead on four DARTs.
- Collaboration with Servier on multiple oncology DARTs.
- Collaboration with Servier on MGA271.
- Global DART partnerships with Pfizer and Boehringer Ingelheim. Learn more